Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region

Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

(2020) Eleonora De Matteis et al.   Expert Review of Neurotherapeutics

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

(2020) Antonio Russo et al.   JOURNAL OF HEADACHE AND PAIN

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab: from scientific evidence to clinical practice—the first Italian real-life data

(2019) Piero Barbanti et al.   NEUROLOGICAL SCIENCES

Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies

(2019) Andrea Negro et al.   Expert Review of Neurotherapeutics

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

(2019) Cindy Tiseo et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in chronic migraine

(2019) Richard B. Lipton et al.   NEUROLOGY

Erenumab in chronic migraine with medication overuse

(2019) Stewart J. Tepper et al.   NEUROLOGY

The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

(2019) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response

(2019) Jan Lewis Brandes et al.   CEPHALALGIA

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2018) Messoud Ashina et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Correction to: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

(2018)   JOURNAL OF HEADACHE AND PAIN

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month

(2016) M Torres-Ferrús et al.   CEPHALALGIA

Chronic migraine: risk factors, mechanisms and treatment

(2016) Arne May et al.   Nature Reviews Neurology